Education
About Us
Working with TipRanks
Follow Us
NovoCure Ltd. (NVCR)
:NVCR
NVCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.88 - $34.13
Previous CloseN/A
Volume205.01K
Average Volume (3M)774.71K
Market Cap
$1.84B
Enterprise Value$2.95B
Total Cash (Recent Filing)$57.61M
Total Debt (Recent Filing)$321.00K
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Jul 24, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding111,485,130
10 Day Avg. Volume796,969
30 Day Avg. Volume774,708
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.51
Price to Cash Flow (P/CF)-153.90
P/FCF Ratio346.30
Enterprise Value/Market Cap1.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.31
Enterprise Value/Ebitda-27.46
Forecast
1Y Price Target
$34.00Price Target Upside83.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
NovoCure News
PremiumCompany Announcements
Novocure’s Q1 2025: Revenue Growth and Strategic Advances
PremiumCompany Announcements
NovoCure Ltd. Earnings Call: Growth Amid Financial Challenges---
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalThe recent approval of Optune Lua in NSCLC and the chance for success in upcoming regulatory decisions present an overall positive view on NVCR.
Revenue GrowthNVCR reported a ~19% increase in year-over-year net revenues, primarily due to the success of Optune Gio's launch in France and improved approval rate in the U.S.
Bears Say
Prescription TrendsPrescriptions for Optune Gio shrunk overall with 1,520 received in the quarter compared to 1,586 in the previous quarter, a 4% decrease.
Regional Revenue PerformanceRevenue in Greater China was significantly below estimates and represented only about half of historical quarterly revenue.
---
Ownership Overview
1.82% Insiders
35.64% Mutual Funds
0.06% Other Institutional Investors
46.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVCR FAQ
What was NovoCure Ltd.’s price range in the past 12 months?
NovoCure Ltd. lowest stock price was $11.88 and its highest was $34.13 in the past 12 months.
What is NovoCure Ltd.’s market cap?
NovoCure Ltd.’s market cap is $1.84B.
When is NovoCure Ltd.’s upcoming earnings report date?
NovoCure Ltd.’s upcoming earnings report date is Jul 24, 2025 which is in 90 days.
How were NovoCure Ltd.’s earnings last quarter?
NovoCure Ltd. released its earnings results on Apr 24, 2025. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.464 by $0.154.
Is NovoCure Ltd. overvalued?
According to Wall Street analysts NovoCure Ltd.’s price is currently Undervalued.
Does NovoCure Ltd. pay dividends?
NovoCure Ltd. does not currently pay dividends.
What is NovoCure Ltd.’s EPS estimate?
NovoCure Ltd.’s EPS estimate is -0.38.
How many shares outstanding does NovoCure Ltd. have?
NovoCure Ltd. has 111,485,130 shares outstanding.
What happened to NovoCure Ltd.’s price movement after its last earnings report?
NovoCure Ltd. reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.464. Following the earnings report the stock price went up 4.389%.
Which hedge fund is a major shareholder of NovoCure Ltd.?
Currently, no hedge funds are holding shares in NVCR
---
NovoCure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$34.00 (83.29% Upside)
$34.00 (83.29% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 59.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $736.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
50.32%
12-Months-Change
Fundamentals
Return on Equity
-46.67%
Trailing 12-Months
Asset Growth
8.26%
Trailing 12-Months
Company Description
NovoCure Ltd.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
---
NVCR Company Deck
---
NVCR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted NovoCure Limited's successful expansion efforts with CE Mark approval in Europe and promising clinical trial results, which are overshadowed by financial losses and margin pressures. The company's strategic focus on expanding indications shows potential for growth, but current financial challenges are notable.Read More>---
NVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
---
NVCR Stock 12 Month Forecast
Average Price Target
$34.00
▲(83.29% Upside)
Technical Analysis
Best Analysts Covering NVCR
1 Year
1 Year Success Rate
10/19 ratings generated profit
1 Year Average Return
+9.69%
reiterated a buy rating 2 months ago
Copying Larry Biegelsen's trades and holding each position for 1 Year would result in 52.63% of your transactions generating a profit, with an average return of +9.69% per trade.
---